•
Guangdong Raynovent Biotech Co., Ltd, a controlling subsidiary of China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), has reportedly raised RMB 370 million (USD 53.72 million) in a Series C financing round. The round was co-led by Yide Private Equity Investment Fund Management (Guangzhou) Co., Ltd and Efung Capital, with…
•
Immunohead Biotechnology Co., Ltd, a cell therapy developer based in Suzhou, has reportedly raised close to RMB 200 million (USD 28.89 million) in a Series A+ financing round. The round was led by SDIC Venture Capital, with participation from the Bio-Town Equity Investment Fund. The proceeds will be used to…
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced the completion of a financing round at RMB 1.5 billion (USD 215.53 million) for its subsidiary Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Kelun maintains majority control of the subsidiary with a 59.75% stake, increased from 55.41%. Merck, Sharp & Dohme (MSD;…
•
Shenzhen-based heart failure mechanical circulatory support solutions provider, Shenzhen Core Medical Technology Co., Ltd, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round. The round was led by investors including Yuanhenglizhen Management, Cornerstone Capital, Salubris Pharma, Nanshan SEI Investment, Beihang Investment, New Alliance Capital, and…
•
China-based molecular diagnostic product developer Guangzhou Mygene Medical Technology Co., Ltd reportedly raised “hundreds of millions” of renminbi in a Series C financing round led by Efund Capital. Other investors included Anggu Fuge Investment, Juyo Capital, Benchi Capital, and Hongtu Runda Capital. The proceeds will be used for research and…
•
Biosion, a global, clinical-stage biotech committed to developing antibody-based therapies targeting immune and oncologic diseases, has announced the completion of a Series B financing round at upwards of RMB 100 million (USD 14.33 million). The funding was led by Guangfa Xinde Investment, with contributions from FangFund, Addor Capital, and Suxin…
•
China-based Shenzhen Würzburg Dynamics has reportedly raised RMB 100 million (USD 14.36 million) in a Series A financing round. The funding was led by 3E Bioventures Capital, with contributions from Tzitzit Asset and Fosun Health Capital. The proceeds will be used for research and development and market construction for multiple…
•
AcornMed, a tumor precision medicine specialist based in Beijing, has reportedly raised RMB 200 million (USD 28.7 million) in a Series B financing round led by Yikai Venture Capital. Other investors included Lichen Investment, Qingdao Hongteng, and Wushi Capital. The proceeds will be used for research and development of tumor…
•
China-based Jiangsu Vcare PharmaTech Co. Ltd has reportedly raised over RMB 200 million (USD 28.67 million) in a Series B financing round. The round was led by Changjiang Venture Capital, with additional investments from Hongcheng Investment, Huadian Investment, Yangtze Investment, and SDIC. The proceeds will be used for clinical development…
•
China-based Shanghai-listed Nanjing Pharmaceutical Co., Ltd (SHA: 600713) is set to acquire a respective 55%, 55%, and 100% stake in three subsidiaries of compatriot firm Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. The deals entail a consideration of RMB 148 million (USD 21.2 million). The subsidiaries involved are Suzhou Tianqing…
•
Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest out-licensing deal between a multinational and a China-based firm. The US giant has returned to sign its third deal of this year with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, securing development, manufacturing, and commercialization rights to…
•
Israel-based start-up Biomica has reportedly raised an undisclosed amount of money via another financing round, led by Shanghai HealthCare Capital and its parent company Evogene. The proceeds will be used for a Phase I clinical study for its tumor immunity project BMC128, GMPc-compliant manufacturing for BMC333 for inflammatory bowel disease…
•
Redpine Medical, a single-use endoscope maker based in Guangzhou, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round led by Yuexiu Industrial Investment Fund. Other investors included Eight Roads, Guoju Venture Capital, Caixin Private Placement, and others. The proceeds will be used for manufacturing capacity…
•
Shenzhen-based chronic disease device maker Sibionics has reportedly raised close to RMB 500 million (USD 71.7 million) in a Series D financing round. The round was led by Shanghai Healthcare Capital and Guangdong Traditional Chinese Medicine Healthcare Fund, with contributions from Industrial Securities Capital, Next Capital, and China New Town…
•
Waker Bioscience, an integration site analysis (ISA) specialist based in Shanghai, has reportedly raised “tens of millions” of renminbi in an angel financing round, solely led by BGI Co-Win. The proceeds will be used for technology upgrades, team building, testing business development, and laboratory platform automation construction. Company Background and…
•
Ronovo Surgical, a minimally invasive surgery device maker based in Shanghai, has reportedly raised “tens of millions” of US dollars in a Pre-Series B financing round led by LongRiver Investments. Other investors included Lilly Asia Ventures, Vivo Capital, Matrix Partners, and GGV Capital. The proceeds will be used for multi-specialty…
•
China-based ophthalmology device maker TowardPi (Beijing) Medical Technology Ltd has reportedly raised close to RMB 300 million (USD 42.96 million) in a Series C financing round. The round was led by Sunrock Capital, with contributions from Tao Capital, Kunlun Capital, and existing investor Aibo Qingshi Venture Capital. This marks a…
•
Ireland-based Endo International plc (NASDAQ: ENDP) has announced a licensing deal between its subsidiary Endo Ventures Ltd (EVL) and Taiwan Liposome Company Ltd (TLC). The agreement centers on TLC’s TLC599, a novel injectable nanomedicine compound currently in Phase III development for osteoarthritis (OA) knee pain. Deal Terms and FinancialsUnder the…
•
China’s Zhuhai Meihua Medical Technology Co., Ltd, a leading clinical microbiology laboratory overall solutions provider, has reportedly raised over RMB 100 million (USD 14.3 million) in a Series B financing round. The round was led by Eight Roads and Sunland Fund, with contributions from Zhuhai Hi tech Financial Investment and…
•
InnerMedical Co., Ltd, a leading chronic disease diagnosis and treatment solutions provider based in Shenzhen, has reportedly raised close to RMB 300 million (USD 42.9 million) in a Series D financing round. The round was led by Green Pine Capital Partners and Simiao Capital, with participation from Cornerstone Investment, Chengshang…